Impact News +++ eHealth, Inc. to Present at Noble Capital Markets′ Emerging Growth Virtual Equity Conference (PR Newswire) +++ EHEALTH Aktie +4,07%

OVID THERAPEUTICS Aktie

>OVID THERA Aktienkurs

1.57 EUR +13.6% (Tradegate)

Ask: 1.6 EUR / 0 Stück

Bid: 1.53 EUR / 0 Stück

Tagesumsatz: 81022 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

OVID THERA Aktie über LYNX handeln

Intraday

1 Jahr

>OVID THERA Performance

1 Woche: +3,3%

1 Monat: +24,5%

3 Monate: +352,0%

6 Monate: +307,1%

1 Jahr: +23,9%

laufendes Jahr: +38,8%

>OVID THERAPEUTICS Aktie

Name:

OVID THERAPEUTICS DL-,001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US6904691010 / A2DQ8S

Symbol/ Ticker:

1OT (Frankfurt) / OVID (NASDAQ)

Kürzel:

FRA:1OT, ETR:1OT, 1OT:GR, NASDAQ:OVID

Index:

Webseite:

https://ovidrx.com/

Profil:

Ovid Therapeutics Inc. is a biopharmaceutical comp..
>Volltext..

Marktkapitalisierung:

82.87 Mio. EUR

Unternehmenswert:

62.33 Mio. EUR

Umsatz:

5.66 Mio. EUR

EBITDA:

-34.89 Mio. EUR

Nettogewinn:

-32.47 Mio. EUR

Gewinn je Aktie:

-0.46 EUR

Schulden:

11.99 Mio. EUR

Liquide Mittel:

24.17 Mio. EUR

Operativer Cashflow:

-34.08 Mio. EUR

Bargeldquote:

4.3

Umsatzwachstum:

965.59%

Gewinnwachstum:

-16.7%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

OVID THERAPEUTICS, OVID THERAPEUTIC, OVID THERA

Letzte Datenerhebung:

03.10.25

>OVID THERA Kennzahlen

Aktien/ Unternehmen:

Aktien: 71.11 Mio. St.

Frei handelbar: 83.71%

Leerverk. Aktien: 0.69%

Rückkaufquote: -0.05%

Mitarbeiter: 23

Umsatz/Mitarb.: 0.02 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 153.3%

Bewertung:

KGV: -

KGV lG: -

KUV: 15.68

KBV: 1.73

PEG-Ratio: -0.1

EV/EBITDA: -

Rentabilität:

Bruttomarge: 91.66%

Gewinnmarge: -574.02%

Operative Marge: -625.03%

Managementeffizenz:

Gesamtkaprendite: -39.05%

Eigenkaprendite: -52.77%

>OVID THERA Peer Group

Es sind 599 Aktien bekannt.

>OVID THERA Chart & Kurs - NASDAQ

>OVID THERA News

03.10.25 - 13:30	Ovid Therapeutics jumps 28% on $175M private placement (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

03.10.25 - 13:24	Positive Studiendaten zu Epilepsie-Medikament beflügeln Aktie von Ovid Therapeutics (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

03.10.25 - 13:09

Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds (GlobeNewswire EN)

Initial closing of approximately $81 million expected to fund current operating plan and clinical pipeline into 2028, with potential for up to $94 million in additional proceeds upon exercise of issued warrants Initial closing of approximately $81 million expected to fund current operating plan and clinical pipeline into 2028, with potential for up to $94 million in additional proceeds upon exercise of issued warrants...

03.10.25 - 13:03

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile (GlobeNewswire EN)

NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today announced positive topline results from its Phase 1 healthy volunteer study evaluating the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) activity of OV329, a next generation GABA-aminotransferase (GABA-AT) inhibitor being developed for drug-resistant epilepsies....

01.10.25 - 06:30

Biotech Stocks Rebound After Hours Amid Broader Sector Tailwinds (RTTNews)

Biotech stocks posted strong after-hours gains Tuesday, with several small-cap names rebounding despite limited news flow. Broader sentiment may have been supported by Pfizer's announcement of U.S. drug price cuts and a $70 billion investment in domestic manufacturing. Ovid Therapeutics, NeuroOne Medical, PepGen, Reviva Pharmaceuticals, and Anika Therapeutics all saw notable moves following mixed regular session action....

13.08.25 - 16:45	Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
	Ovid Therapeutics (OVID) delivered earnings and revenue surprises of +62.50% and +4,225.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?...

13.08.25 - 16:12	Ovid Therapeutics GAAP EPS of -$0.06, revenue of $6.3M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

23.07.25 - 14:33	Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference (GlobeNewswire EN)
	Ovid Therapeutics to participate in the BTIG Virtual Biotech Conference...

25.06.25 - 14:07

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties (Cision)

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties Non-dilutive funding extends Ovid's operational runway; Immedica assumes certain ganaxolone IP costs NEW YORK, U.S and STOCKHOLM, Sweden, June 25, 2025 – Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today announced that it has entered into a definitive agreement with Immedica Pharma AB ('Immedica'), a leading global rare disease company, for the sale of its future...

05.06.25 - 13:33	Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025 (GlobeNewswire EN)
	Emerging Biomarkers in the Clinical Development of Epilepsy Medicines and OV329 Program Highlights Emerging Biomarkers in the Clinical Development of Epilepsy Medicines and OV329 Program Highlights...

13.05.25 - 14:18	Ovid Therapeutics GAAP EPS of -$0.14 in-line, revenue of $0.13M beats by $0.1M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.05.25 - 17:15	Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
	Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

11.03.25 - 15:45	Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
	Ovid Therapeutics (OVID) delivered earnings and revenue surprises of 18.75% and 45.71%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?...

11.03.25 - 13:18	Ovid Therapeutics GAAP EPS of -$0.13 beats by $0.03, revenue of $0.07M misses by $0.12M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

03.03.25 - 14:03	Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors (GlobeNewswire EN)
	NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appointment of Stelios Papadopoulos, Ph.D. to its Board of Directors....

01.03.25 - 00:01	Insiderhandel: CBFO verkauft Aktien von Ovid Therapeutics im Wert von 2185 USD (Insiderkauf)
	Rona, Jeffrey A. - Vorstand - Tag der Transaktion: 2025-02-26...

01.03.25 - 00:01	Insiderhandel: President and COO verkauft Aktien von Ovid Therapeutics im Wert von 2956 USD (Insiderkauf)
	Alexander, Margaret A. - Vorstand - Tag der Transaktion: 2025-02-26...

27.02.25 - 14:03

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire EN)

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 3:10 p.m. ET in Boston, Massachusetts....

05.02.25 - 14:03	Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire EN)
	NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that management will participate in a virtual presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025, at 4:00 p.m. ET....

29.01.25 - 16:01	Insiderhandel: President and COO kauft Aktien von Ovid Therapeutics im Wert von 4971 USD (Insiderkauf)
	Alexander, Margaret A. - Vorstand - Tag der Transaktion: 2025-01-27...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wer heilt, hat recht. - Hippokrates

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram